MXPA04000707A - Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas. - Google Patents
Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas.Info
- Publication number
- MXPA04000707A MXPA04000707A MXPA04000707A MXPA04000707A MXPA04000707A MX PA04000707 A MXPA04000707 A MX PA04000707A MX PA04000707 A MXPA04000707 A MX PA04000707A MX PA04000707 A MXPA04000707 A MX PA04000707A MX PA04000707 A MXPA04000707 A MX PA04000707A
- Authority
- MX
- Mexico
- Prior art keywords
- receptor antagonists
- substituted urea
- neuropeptide
- urea neuropeptide
- npy
- Prior art date
Links
- 239000002464 receptor antagonist Substances 0.000 title abstract 3
- 229940044551 receptor antagonist Drugs 0.000 title abstract 3
- 101710151321 Melanostatin Proteins 0.000 title 1
- 102400000064 Neuropeptide Y Human genes 0.000 title 1
- 239000004202 carbamide Substances 0.000 title 1
- URPYMXQQVHTUDU-OFGSCBOVSA-N nucleopeptide y Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(N)=O)NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@@H](N)CC=1C=CC(O)=CC=1)C1=CC=C(O)C=C1 URPYMXQQVHTUDU-OFGSCBOVSA-N 0.000 title 1
- 150000003672 ureas Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000030814 Eating disease Diseases 0.000 abstract 1
- 208000019454 Feeding and Eating disease Diseases 0.000 abstract 1
- 206010020710 Hyperphagia Diseases 0.000 abstract 1
- 102100029549 Neuropeptide Y receptor type 5 Human genes 0.000 abstract 1
- 108010046593 Neuropeptide Y5 receptor Proteins 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010012601 diabetes mellitus Diseases 0.000 abstract 1
- 235000014632 disordered eating Nutrition 0.000 abstract 1
- 208000030159 metabolic disease Diseases 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/96—Sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Diabetes (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La presente invencion describe compuestos que son nuevos antagonistas del receptor Y5 del NPY asi como tambien metodos para preparar dichos compuestos; en otra modalidad, la invencion describe composiciones farmaceuticas que comprenden dichos antagonistas del receptor Y5 del NPY asi como tambien metodos para utilizar las mimas para tratar obesidad, trastornos metabolicos, trastornos de la alimentacion tales como hiperfagia y diabetes.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30843301P | 2001-07-26 | 2001-07-26 | |
| PCT/US2002/023552 WO2003009845A1 (en) | 2001-07-26 | 2002-07-24 | Substituted urea neuropeptide y y5 receptor antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA04000707A true MXPA04000707A (es) | 2004-04-20 |
Family
ID=23193972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA04000707A MXPA04000707A (es) | 2001-07-26 | 2002-07-24 | Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas. |
Country Status (16)
| Country | Link |
|---|---|
| US (2) | US6667319B2 (es) |
| EP (1) | EP1418913A1 (es) |
| JP (1) | JP2005500338A (es) |
| CN (2) | CN1911913A (es) |
| AR (1) | AR036191A1 (es) |
| AU (1) | AU2002355286B2 (es) |
| CA (1) | CA2454830C (es) |
| HU (1) | HUP0401643A3 (es) |
| IL (1) | IL159643A0 (es) |
| IS (1) | IS7096A (es) |
| MX (1) | MXPA04000707A (es) |
| NZ (1) | NZ530429A (es) |
| PE (1) | PE20030385A1 (es) |
| PL (1) | PL368201A1 (es) |
| TW (1) | TWI300064B (es) |
| WO (1) | WO2003009845A1 (es) |
Families Citing this family (45)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0121709D0 (en) * | 2001-09-07 | 2001-10-31 | Imp College Innovations Ltd | Food inhibition agent |
| DE60230818D1 (de) * | 2001-09-24 | 2009-02-26 | Imp Innovations Ltd | Pyy3-36 zur zur reduzierung oder vorbeugung von fettleibigkeit |
| US8058233B2 (en) | 2002-01-10 | 2011-11-15 | Oregon Health And Science University | Modification of feeding behavior using PYY and GLP-1 |
| US7166575B2 (en) * | 2002-12-17 | 2007-01-23 | Nastech Pharmaceutical Company Inc. | Compositions and methods for enhanced mucosal delivery of peptide YY and methods for treating and preventing obesity |
| GB0300571D0 (en) * | 2003-01-10 | 2003-02-12 | Imp College Innovations Ltd | Modification of feeding behaviour |
| US7772188B2 (en) | 2003-01-28 | 2010-08-10 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
| CA2520763A1 (en) | 2003-04-03 | 2004-10-21 | The Regents Of The University Of California | Improved inhibitors for the soluble epoxide hydrolase |
| CA2559665A1 (en) | 2004-03-16 | 2005-09-29 | The Regents Of The University Of California | Reducing nephropathy with inhibitors of soluble epoxide hydrolase and epoxyeicosanoids |
| EP1734963A4 (en) | 2004-04-02 | 2008-06-18 | Merck & Co Inc | METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER |
| TW200630337A (en) * | 2004-10-14 | 2006-09-01 | Euro Celtique Sa | Piperidinyl compounds and the use thereof |
| EP1814875A4 (en) | 2004-10-20 | 2010-02-17 | Univ California | IMPROVED INHIBITORS OF SOLUBLE EPOXY HYDROLASE |
| FR2884516B1 (fr) * | 2005-04-15 | 2007-06-22 | Cerep Sa | Antagonistes npy, preparation et utilisations |
| GB0511986D0 (en) * | 2005-06-13 | 2005-07-20 | Imp College Innovations Ltd | Novel compounds and their effects on feeding behaviour |
| BRPI0612599A2 (pt) * | 2005-06-30 | 2010-11-23 | Prosidion Ltd | composto, composição farmacêutica compreendendo o mesmo, método de tratamento e uso do mesmo |
| FR2894964B1 (fr) * | 2005-12-19 | 2008-02-22 | Cerep Sa | Composes a base de quatre cycles aromatiques, preparation et utilisations |
| TW200808723A (en) * | 2006-03-13 | 2008-02-16 | Univ California | Conformationally restricted urea inhibitors of soluble epoxide hydrolase |
| WO2007110449A1 (en) | 2006-03-29 | 2007-10-04 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use |
| TW200812963A (en) | 2006-04-13 | 2008-03-16 | Euro Celtique Sa | Benzenesulfonamide compounds and the use thereof |
| WO2007118853A1 (en) | 2006-04-13 | 2007-10-25 | Euro-Celtique S.A. | Benzenesulfonamide compounds and their use as blockers of calcium channels |
| JP5207382B2 (ja) * | 2006-08-30 | 2013-06-12 | 塩野義製薬株式会社 | ウレア誘導体 |
| TWI428346B (zh) * | 2006-12-13 | 2014-03-01 | Imp Innovations Ltd | 新穎化合物及其等對進食行為影響 |
| WO2008124118A1 (en) * | 2007-04-09 | 2008-10-16 | Purdue Pharma L.P. | Benzenesulfonyl compounds and the use therof |
| US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
| WO2008151257A2 (en) | 2007-06-04 | 2008-12-11 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| US8765736B2 (en) | 2007-09-28 | 2014-07-01 | Purdue Pharma L.P. | Benzenesulfonamide compounds and the use thereof |
| WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| CA2730603C (en) | 2008-07-16 | 2019-09-24 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
| CA2741125A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
| US9296693B2 (en) | 2010-01-29 | 2016-03-29 | The Regents Of The University Of California | Acyl piperidine inhibitors of soluble epoxide hydrolase |
| US8895596B2 (en) | 2010-02-25 | 2014-11-25 | Merck Sharp & Dohme Corp | Cyclic benzimidazole derivatives useful as anti-diabetic agents |
| US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
| BR112013021236B1 (pt) | 2011-02-25 | 2021-05-25 | Merck Sharp & Dohme Corp | composto derivado de benzimidazol, e, composição |
| CN102675190A (zh) * | 2012-05-23 | 2012-09-19 | 盛世泰科生物医药技术(苏州)有限公司 | 一种3-（二甲氨基）次甲基-n-甲磺酰基哌啶-4-酮的合成方法 |
| US9527875B2 (en) | 2012-08-02 | 2016-12-27 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| MX2015010935A (es) | 2013-02-22 | 2015-10-29 | Merck Sharp & Dohme | Compuestos biciclicos antidiabeticos. |
| US9650375B2 (en) | 2013-03-14 | 2017-05-16 | Merck Sharp & Dohme Corp. | Indole derivatives useful as anti-diabetic agents |
| WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
| EP2970384A1 (en) | 2013-03-15 | 2016-01-20 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
| AU2014274812B2 (en) | 2013-06-05 | 2018-09-27 | Bausch Health Ireland Limited | Ultra-pure agonists of guanylate cyclase C, method of making and using same |
| WO2015051496A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
| EP3551176A4 (en) | 2016-12-06 | 2020-06-24 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
| WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
| WO2019140188A1 (en) | 2018-01-11 | 2019-07-18 | Centaurus Therapeutics | Inhibitors of dihydroceramide desaturase for treating disease |
| WO2022076365A1 (en) * | 2020-10-06 | 2022-04-14 | Eastman Chemical Company | Aromatic enol ethers |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE2928485A1 (de) | 1979-07-14 | 1981-01-29 | Bayer Ag | Verwendung von harnstoffderivaten als arzneimittel bei der behandlung von fettstoffwechselstoerungen |
| US4623662A (en) | 1985-05-23 | 1986-11-18 | American Cyanamid Company | Antiatherosclerotic ureas and thioureas |
| US5602024A (en) | 1994-12-02 | 1997-02-11 | Synaptic Pharmaceutical Corporation | DNA encoding a hypothalamic atypical neuropeptide Y/peptide YY receptor (Y5) and uses thereof |
| WO1999064394A1 (en) | 1998-06-08 | 1999-12-16 | Schering Corporation | Neuropeptide y5 receptor antagonists |
| US6191160B1 (en) | 1998-11-10 | 2001-02-20 | Merck & Co., Inc. | Spiro-indolines as Y5 receptor antagonists |
| CN1474810A (zh) * | 2000-09-14 | 2004-02-11 | ���鹫˾ | 取代脲,神经肽yy5受体拮抗剂 |
-
2002
- 2002-07-24 NZ NZ530429A patent/NZ530429A/en unknown
- 2002-07-24 EP EP02752562A patent/EP1418913A1/en not_active Withdrawn
- 2002-07-24 MX MXPA04000707A patent/MXPA04000707A/es active IP Right Grant
- 2002-07-24 PL PL02368201A patent/PL368201A1/xx not_active Application Discontinuation
- 2002-07-24 HU HU0401643A patent/HUP0401643A3/hu unknown
- 2002-07-24 CN CNA2006101215468A patent/CN1911913A/zh active Pending
- 2002-07-24 CN CNA028189647A patent/CN1558764A/zh active Pending
- 2002-07-24 JP JP2003515237A patent/JP2005500338A/ja active Pending
- 2002-07-24 AU AU2002355286A patent/AU2002355286B2/en not_active Ceased
- 2002-07-24 CA CA002454830A patent/CA2454830C/en not_active Expired - Fee Related
- 2002-07-24 US US10/202,239 patent/US6667319B2/en not_active Expired - Fee Related
- 2002-07-24 IL IL15964302A patent/IL159643A0/xx unknown
- 2002-07-24 AR ARP020102785A patent/AR036191A1/es unknown
- 2002-07-24 WO PCT/US2002/023552 patent/WO2003009845A1/en not_active Ceased
- 2002-07-24 TW TW091116480A patent/TWI300064B/zh active
- 2002-07-24 PE PE2002000653A patent/PE20030385A1/es not_active Application Discontinuation
-
2003
- 2003-10-24 US US10/692,559 patent/US7304076B2/en not_active Expired - Fee Related
- 2003-12-31 IS IS7096A patent/IS7096A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| IL159643A0 (en) | 2004-06-01 |
| US6667319B2 (en) | 2003-12-23 |
| US20040102474A1 (en) | 2004-05-27 |
| NZ530429A (en) | 2005-09-30 |
| IS7096A (is) | 2003-12-31 |
| US20030207860A1 (en) | 2003-11-06 |
| PE20030385A1 (es) | 2003-05-08 |
| CN1911913A (zh) | 2007-02-14 |
| CN1558764A (zh) | 2004-12-29 |
| WO2003009845A1 (en) | 2003-02-06 |
| CA2454830A1 (en) | 2003-02-06 |
| PL368201A1 (en) | 2005-03-21 |
| EP1418913A1 (en) | 2004-05-19 |
| JP2005500338A (ja) | 2005-01-06 |
| AU2002355286B2 (en) | 2005-10-13 |
| AR036191A1 (es) | 2004-08-18 |
| US7304076B2 (en) | 2007-12-04 |
| HUP0401643A2 (hu) | 2004-12-28 |
| CA2454830C (en) | 2010-02-02 |
| TWI300064B (en) | 2008-08-21 |
| HUP0401643A3 (en) | 2009-06-29 |
| WO2003009845A9 (en) | 2004-03-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA04000707A (es) | Nuevos antagonistas del receptor y5 del neuropeptido y referencia cruzada a solicitudes relacionadas. | |
| MXPA04004956A (es) | Antagonistas de la hormona concentradora de melanina basados en la piperidina para tratamiento de la obesidad y de trastornos del sistema nervioso central. | |
| MXPA04003858A (es) | Antagonistas de mch para el tratamiento de obesidad. | |
| WO2004005262A3 (en) | New neuropeptide y y5 receptor antagonists | |
| WO2003028641A3 (en) | Mch receptor antagonists | |
| IL182317A0 (en) | Cgrp receptor antagonists | |
| HK1054333A1 (zh) | 杂芳基脲神经肽yy5受体拮抗剂 | |
| MXPA05010859A (es) | Antagonistas mchr1 heterociclicos. | |
| WO2006029153A3 (en) | Monocyclic anilide spirolactam cgrp receptor antagonists | |
| MXPA04002583A (es) | Derivados de 4,5-dihidro-1h-pirazol novedosos que tienen actividad antagonistica del canabinoide (cb1). | |
| JO2355B1 (en) | Hereditary calcitonin polypeptide receptor antagonists | |
| WO2004091514A3 (en) | Cgrp receptor antagonists | |
| ATE312090T1 (de) | 4-(piperidyl- und pyrrolidyl-alkyl-ureido)- chinoline als urotensin ii rezeptor antagonisten | |
| WO2006099268A3 (en) | Cgrp receptor antagonists | |
| EP1398029A8 (en) | NR3B1 nuclear receptor binding 3-substituted pyrazole derivatives | |
| WO2006047196A3 (en) | Cgrp receptor antagonists | |
| DE60213629D1 (de) | Piperidinverbindungen als muscarinantagonisten | |
| TW200720260A (en) | Prokineticin 1 receptor antagonists | |
| TW200716566A (en) | Prokineticin 2 receptor antagonists | |
| WO2006041830A3 (en) | Cgrp receptor antagonists | |
| WO2003057149A3 (en) | 4-substituted fused heteropyrimidines and fused hetero-4-pyrimidones | |
| WO2006044449A3 (en) | Cgrp receptor antagonists | |
| NZ514696A (en) | IL-8 receptor antagonists | |
| WO2004026837A3 (en) | Histamine h3 receptor antagonists, preparaton and therapeutic uses | |
| MXPA05009193A (es) | Biariltetrahidroisoquinolina piperidinas como antagonistas receptores selectivos de la hormona que concentra la melanina para el tratamiento de la obesidad y trastornos relacionados. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |